Samuel Broder, director of the National Cancer Institute in the late 1980s, stated that Lasker "has meant essentially
everything . . . to the . . . National Institutes of Health. She is a genius who forced the realization that the federal
government must commit itself to medical research to benefit all Americans."
Number of Image Pages:
1 (66,672 Bytes)
1990-08-27 (August 27, 1990)
National Cancer Institute (U.S.)
Original Repository: Columbia University. Rare Book and Manuscript Library. Mary Lasker Papers
This item is in the public domain. It may be used without permission.
This letter is to invite you to attend and participate in a workshop on cancer vaccines being sponsored by the National Cancer
Institute, to be held October 29-30, 1990 at the Hyatt Regency Hotel in Bethesda, Maryland.
Vaccination is a classical technique to prevent infectious disease. It has been used successfully against a variety of bacterial
and viral diseases. It is important that we now give serious consideration to the utilization of a vaccine approach for cancer
prevention and control.
Recent advances in molecular biology and immunology, as well as recent results with tumor vaccines in some clinical trials
and in preclinical animal tumor models, provide a strong impetus for focusing efforts and resources on vaccines as an important
new approach to the prevention and treatment of cancer. Such cancer vaccines would be aimed at preventing the recurrence and
metastatic spread of cancer in patients diagnosed with a primary tumor, and at preventing the development of cancer in individuals
at high risk for malignant disease. At this meeting, a number of scientific experts will provide the most up-to-date information
on topics such as viral vaccines, tumor antigens as vaccine targets, stimulation of activated cells, and prospects for cancer
vaccine development. In addition, participants will be encouraged to suggest fruitful areas for future investigation, as well
as necessary resources to support these investigations.
Because of your interest in and support for cancer research, I wanted to bring this important meeting to your attention, and
to invite you to attend and participate. You will receive an accompanying letter from Dr. Jack Gruber, Chief of NCI's
Biological Carcinogenesis Branch, which will provide details of the meeting arrangements. I hope you can reserve October 29
and 30 for this purpose, and I look forward to seeing you there.